Spero Therapeutics, Inc. - 8-K Filing

Spero Therapeutics reports Q3 2026 net loss of $44.3 million and announces SP001 Phase 2 initiation target for Q2 2027 (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits(d)Exhibits ExhibitNo)

SEC EDGAR · November 12, 2026, 21:43 UTC

Tickers: $SPRO

Read the full article at SEC EDGAR

More Regulatory news

Gores Holdings XI, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:57 UTC
Peraso Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:57 UTC
SOLESENCE, INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:56 UTC
BioRestorative Therapies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:56 UTC
Jaws Mustang Acquisition Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:55 UTC
Private Bancorp of America, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:53 UTC
USA Rare Earth, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:54 UTC
SCHWAB CHARLES CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:52 UTC
SPRUCE POWER HOLDING CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:52 UTC
Xterax Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 21:51 UTC